(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...
Kezar (KZR) stock fell 11% after the company's board rejected an unsolicited takeover offer from Concentra Biosciences and ...
Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences. Concentra’s parent company Tang Capital Partners has a track ...
Earlier on Thursday, Kezar Life Sciences rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences for cash consideration of $1.10 per share, plus a contingent ...
1 Day CON 0.52% DJIA 0.09% S&P Mid Cap 400 0.01% Health Care/Life Sciences 0.22% ...
1 Day CON -2.54% DJIA 0.37% S&P Mid Cap 400 0.15% Health Care/Life Sciences -0.15% ...
calendar.circle.fill calendar.badge.plus calendar.badge.minus arrowshape.turn.up.left arrowshape.turn.up.left.fill arrowshape.turn.up.left.circle arrowshape.turn.up ...
ITWIllinois Tool Works Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback